SCHEMBL20047657

SCHEMBL20047657

CC(C)Nc1ccccc1OC(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.45
▸ EPHX2 P34913 2/20 0.43
▸ DDB1 Q16531 1/20 0.40
▸ CRBN Q96SW2 1/20 0.40
▸ KCNK3 O14649 3/20 0.40
▸ KCNK9 Q9NPC2 3/20 0.40
▸ C1R P00736 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.38
▸ IDO1 P14902 1/20 0.37
▸ P2RX7 Q99572 1/20 0.36
▸ GBA1 P04062 1/20 0.36
▸ ANO1 Q5XXA6 3/20 0.36
▸ EGFR P00533 1/20 0.36
▸ SLC40A1 Q9NP59 1/20 0.35
▸ PTGES2 Q9H7Z7 1/20 0.35
▸ DGAT1 O75907 1/20 0.35
▸ UBE2M P61081 1/20 0.35
▸ DCUN1D1 Q96GG9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21789897 0.84 MPL (0.38) GAAEPHX2DDB1CRBNKCNK3
SCHEMBL5645988 0.79 GAA (0.49) GAAEPHX2DDB1CRBNKCNK3
SCHEMBL9592758 0.78 TDP1 (0.44) GAATDP1IDO1
SCHEMBL3192934 0.78 EPHX2 (0.57) GAAEPHX2DDB1CRBNC1R
SCHEMBL1644887 0.76 ALDH1A1 (0.50) GAATDP1
SCHEMBL13979 0.76 GAA (0.51) GAAEPHX2KCNK3KCNK9DGAT1
SCHEMBL20043263 0.76 GAA (0.46) GAAEPHX2DDB1CRBNKCNK3
SCHEMBL12780378 0.75 MDM4 (0.54) GAAEPHX2KCNK3KCNK9DGAT1
SCHEMBL16625020 0.75 ALDH1A1 (0.44) TDP1IDO1PTGES2
SCHEMBL29573342 0.75 GAA (0.49) GAAEPHX2DDB1CRBNC1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019242689-A1 CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF 北京赛特明强医药科技有限公司 2019-12-26 — — WO disclosed
US-10450306-B2 Isoxazole analogs as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2019-10-22 — — US disclosed
US-20180099957-A1 ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-04-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10450306-B2 Isoxazole analogs as FXR agonists and methods of use thereof GPBAR1, SLC10A1, NR1H4 GAA 614/4885EPHX2 778/4885DDB1 3464/4885
US-20180099957-A1 ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF GPBAR1, SLC10A1, NR1H4 GAA 614/4885EPHX2 778/4885DDB1 3464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback